NASDAQ:BNTC - Benitec Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.52 -0.01 (-0.40 %)
(As of 05/27/2018 04:12 AM ET)
Previous Close$2.52
Today's Range$2.5010 - $2.53
52-Week Range$1.85 - $4.20
Volume11,409 shs
Average Volume12,052 shs
Market Capitalization$27.90 million
P/E RatioN/A
Dividend YieldN/A
Beta3.45

About Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BNTC
CUSIPN/A
Phone61-2-9555-6986

Debt

Debt-to-Equity RatioN/A
Current Ratio9.64
Quick Ratio11.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.36 million
Price / Sales3.32
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book1.59

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,280,000.00
Net Margins-118.06%
Return on Equity-42.81%
Return on Assets-39.88%

Miscellaneous

Employees18
Outstanding Shares11,030,000

Benitec Biopharma (NASDAQ:BNTC) Frequently Asked Questions

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

When is Benitec Biopharma's next earnings date?

Benitec Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Benitec Biopharma.

Who are some of Benitec Biopharma's key competitors?

Who are Benitec Biopharma's key executives?

Benitec Biopharma's management team includes the folowing people:
  • Mr. Gregory West CA, CEO & Company Sec.
  • Dr. David A. Suhy B.Sc., Ph.D., Chief Scientific Officer
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Annabel Murphy, Head of Investor Relations & Corp. Communications
  • Dr. Michael Graham BSc (Hons), Ph.D., Head of Discovery and Founding Scientist

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Has Benitec Biopharma been receiving favorable news coverage?

News coverage about BNTC stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Benitec Biopharma earned a news impact score of 0.24 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Benitec Biopharma?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $2.52.

How big of a company is Benitec Biopharma?

Benitec Biopharma has a market capitalization of $27.90 million and generates $8.36 million in revenue each year. Benitec Biopharma employs 18 workers across the globe.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is 99 Mount Street Suite 1201, Sydney C3, 2060. The biotechnology company can be reached via phone at 61-2-9555-6986 or via email at [email protected]


MarketBeat Community Rating for Benitec Biopharma (BNTC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about Benitec Biopharma and other stocks. Vote "Outperform" if you believe BNTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Benitec Biopharma (NASDAQ:BNTC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Benitec Biopharma in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Benitec Biopharma (NASDAQ:BNTC) Consensus Price Target History

Price Target History for Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma (NASDAQ:BNTC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Benitec Biopharma (NASDAQ:BNTC) Earnings History and Estimates Chart

Earnings by Quarter for Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma (NASDAQ BNTC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018        
2/22/2018Q2 2018($0.22)$1.06 millionViewN/AView Earnings Details
11/29/2017Q1 2018($0.22)$0.69 millionViewN/AView Earnings Details
8/29/2017Q4 2017($0.20)$1.01 millionViewN/AView Earnings Details
5/30/2017Q3 2017($0.01)$2.81 millionViewN/AView Earnings Details
2/23/2017Q2 2017($0.36)$0.18 millionViewN/AView Earnings Details
11/22/2016Q1 2017$0.08$4.39 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Benitec Biopharma (NASDAQ:BNTC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Benitec Biopharma (NASDAQ BNTC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 1.18%
Insider Trading History for Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma (NASDAQ BNTC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Benitec Biopharma (NASDAQ BNTC) News Headlines

Source:
DateHeadline
Benitec to present OPMD data at the American Society of Gene and Cell Therapy MeetingBenitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting
finance.yahoo.com - May 15 at 10:14 AM
Benitec to Host Investor Webinar on the Companys Oculopharyngeal Muscular Dystrophy (OPMD) ProgramBenitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program
finance.yahoo.com - May 3 at 9:31 AM
ASX/NASDAQ AnnouncementASX/NASDAQ Announcement
finance.yahoo.com - April 24 at 9:37 AM
RNAi For Hepatitis B - A False Hope For A Cure?RNAi For Hepatitis B - A False Hope For A Cure?
seekingalpha.com - April 6 at 4:30 PM
Benitec Biopharma Launches its Phase 2 Oncology Study in AustraliaBenitec Biopharma Launches its Phase 2 Oncology Study in Australia
finance.yahoo.com - March 5 at 9:57 AM
Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational updateBenitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
finance.yahoo.com - February 22 at 9:27 AM
Federal R&D Tax Credit ReceivedFederal R&D Tax Credit Received
finance.yahoo.com - January 24 at 9:25 AM
Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophyBenitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy
finance.yahoo.com - January 16 at 9:52 AM
Benitec Biopharma (BNTC) Downgraded to Sell at ValuEngineBenitec Biopharma (BNTC) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
Benitec Biopharma provides update on OPMD orphan disease programBenitec Biopharma provides update on OPMD orphan disease program
finance.yahoo.com - November 27 at 6:30 PM
U.S. patent granted for Benitec hepatitis B programU.S. patent granted for Benitec hepatitis B program
finance.yahoo.com - October 18 at 5:59 PM
Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017
finance.yahoo.com - September 5 at 6:16 PM
Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 1 at 4:55 PM
Benitec Biopharma Limited (BNTC) Earns "Hold" Rating from Maxim GroupBenitec Biopharma Limited (BNTC) Earns "Hold" Rating from Maxim Group
www.americanbankingnews.com - August 30 at 11:20 AM
Benitec Biopharma advances OPMD orphan disease programBenitec Biopharma advances OPMD orphan disease program
finance.yahoo.com - August 8 at 4:23 PM
Mid-Day Market Update: Shutterfly Drops On Downbeat Earnings; Mead Johnson Shares Spike HigherMid-Day Market Update: Shutterfly Drops On Downbeat Earnings; Mead Johnson Shares Spike Higher
www.benzinga.com - February 2 at 9:14 PM
Mid-Afternoon Market Update: Weatherford Rises Following Q4 Results; Ralph Lauren Shares PlungeMid-Afternoon Market Update: Weatherford Rises Following Q4 Results; Ralph Lauren Shares Plunge
www.nasdaq.com - February 2 at 4:09 PM
Benitec Biopharma (BNTC) Gains After Announces Progress on ddRNAi TechnologyBenitec Biopharma (BNTC) Gains After Announces Progress on ddRNAi Technology
www.streetinsider.com - February 2 at 4:09 PM
Tuesday’s Top Biopharma MoversTuesday’s Top Biopharma Movers
247wallst.com - January 19 at 5:03 PM
Benitec Biopharma (BNTC) Leaped After European Orphan Drug DesignationBenitec Biopharma (BNTC) Leaped After European Orphan Drug Designation
www.rttnews.com - January 19 at 5:03 PM
Benitec Receives Orphan Drug Designation in the...Benitec Receives Orphan Drug Designation in the...
www.benzinga.com - January 18 at 3:24 PM
Benitec Biopharma (BNTC) BB-301 Granted Orphan Drug Designation in EUBenitec Biopharma (BNTC) BB-301 Granted Orphan Drug Designation in EU
www.streetinsider.com - January 18 at 3:24 PM
Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular DystrophyBenitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy
us.rd.yahoo.com - January 17 at 9:32 AM
Benitec in-licenses clinical program for head and neck cancer from NantWorksBenitec in-licenses clinical program for head and neck cancer from NantWorks
us.rd.yahoo.com - December 23 at 4:07 PM
7:13 am Benitec Biopharma in-licenses clinical program for head and neck cancer from NantWorks; financial terms not disclosed7:13 am Benitec Biopharma in-licenses clinical program for head and neck cancer from NantWorks; financial terms not disclosed
us.rd.yahoo.com - December 23 at 4:07 PM

SEC Filings

Benitec Biopharma (NASDAQ:BNTC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Benitec Biopharma (NASDAQ BNTC) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.